Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Harvard Apparatus Regenerative Technology's (HART) Lab-Grown Organ Technology Featured In MIT Technology Review

|Includes: Biostage, Inc. (BSTG)

Clinical-stage biotechnology company Harvard Apparatus Regenerative Technology, Inc. announced it has been featured in an article published by MIT Technology Review that was published on Jan. 16, 2014.

Entitled "Manufacturing Organs," the article highlighted HART's new focus and noted the company is increasing its production of synthetic tracheas to supply clinical trials.

HART has given eight patients a new chance at life since 2008, the article said, as surgeons have replaced the patients' badly damaged tracheas with manmade tracheas from HART. The company's experimental technology is now transitioning from research labs to a Boston-area manufacturing facility as HART gets ready to produce the scaffolds needed to grow these synthetic organs on a large scale. The company is testing its synthetic trachea system in Russia and has plans in view for tests in the European Union and the United States.

HART's synthetic tracheas are created using a patient's own stem cells - and the technology could be adapted for creating other organs in the future, potentially meeting a huge and critical medical need for thousands of patients who are waiting for organ transplants.

The article can be viewed in its entirety at www.technologyreview.com/news/522576/man.../

For more information, visit HART's website at harvardapparatusregen.com

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com